Abstract: Provided are a cell strain for producing a biosimilar drug of Ustekinumab and a production method therefor. Specifically, provided is a Chinese hamster ovary cell S cell strain. The cell strain expresses a full human monoclonal antibody directed against the P40 subunit shared by human IL-12 and human IL-23. The fully human monoclonal antibody directed against the P40 subunit shared by human IL-12 and human IL-23 is a biosimilar drug of Ustekinumab, which not only exhibits high consistency with Ustekinumab in pre-clinical research, but also passes pharmacokinetic bioequivalence and safety similarity evaluation in clinical research. The biosimilar drug of Ustekinumab is the first one that has entered clinical trials in China, is the only one that has completed the I stage clinical trial, and is also one of the biosimilar drugs of Ustekinumab, which has the fastest progress in new drug application in the world.

Abstract: The present invention provides a novel GLP-1 analogue fusion protein and a method for preparing the fusion protein. The fusion protein consists of three regions as follows: GLP-1 analogue-connecting peptide-HSA (Human Serum Albumin). Compounds which contain GLP-1 analogues prepared by adopting the present invention have the advantages of very low production cost, higher biological activity and better in-vivo and in-vitro stability. The fusion protein can be used for treating diabetes, obesity, irritable bowel syndrome and other diseases which can be benefited by reducing plasma glucose, inhibiting stomach and/or intestine movement and inhibiting stomach and/or intestine emptying or inhibiting food intake.

Abstract: The present invention provides a novel GLP-1 analogue fusion protein and a method for preparing the fusion protein. The fusion protein consists of three regions as follows: GLP-1 analogue-linker peptide-HSA (Human Serum Albumin). Compounds which contain GLP-1 analogues prepared by adopting the present invention have the advantages of very low production cost, higher biological activity and better in-vivo and in-vitro stability. The fusion protein can be used for treating diabetes, obesity, irritable bowel syndrome and other diseases which can be benefited by reducing plasma glucose, inhibiting stomach and/or intestine movement and inhibiting stomach and/or intestine emptying or inhibiting food intake.